Plus Therapeutics Inc Total Liabilities
Plus Therapeutics Inc total liabilities. Based on the latest financial reports, Plus Therapeutics Inc (PSTV) has total liabilities worth $8.57 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Plus Therapeutics Inc (PSTV) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Plus Therapeutics Inc (1998–2025)
Total liabilities of Plus Therapeutics Inc from 1998 to 2025. This chart illustrates how Plus Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Plus Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Plus Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Winix Inc
KQ:044340
|
Korea | ₩463.08 Billion |
|
Park Street A/S
CO:PARKST-A
|
Denmark | Dkr1.45 Billion |
|
The Steel Public Company Limited
BK:THE
|
Thailand | ฿1.80 Billion |
|
Pan Brothers Tbk
JK:PBRX
|
Indonesia | Rp130.50 Million |
|
Xiabuxiabu Catering Management (China) Holdings Co. Ltd
F:0XI
|
Germany | €2.32 Billion |
|
Holaluz-Clidom S.A
MC:HLZ
|
Spain | €91.15 Million |
|
Synel M.L.L Payway Ltd
TA:SNEL
|
Israel | ILA56.81 Million |
|
Italian-Thai Development Public Company Limited
F:NYVF
|
Germany | €81.48 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Plus Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Plus Therapeutics Inc.
Liquidity & Leverage Metrics
Plus Therapeutics Inc Total Liabilities Ratios Explained
Plus Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Plus Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Plus Therapeutics Inc (1998–2025)
The table below shows the annual total liabilities of Plus Therapeutics Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.33 Million | -20.88% |
| 2024-12-31 | $15.58 Million | +22.35% |
| 2023-12-31 | $12.74 Million | -26.90% |
| 2022-12-31 | $17.42 Million | +56.32% |
| 2021-12-31 | $11.14 Million | +22.82% |
| 2020-12-31 | $9.07 Million | -58.88% |
| 2019-12-31 | $22.07 Million | +17.60% |
| 2018-12-31 | $18.77 Million | +0.81% |
| 2017-12-31 | $18.61 Million | -21.20% |
| 2016-12-31 | $23.62 Million | -7.33% |
| 2015-12-31 | $25.49 Million | -42.61% |
| 2014-12-31 | $44.42 Million | +14.11% |
| 2013-12-31 | $38.93 Million | +5.80% |
| 2012-12-31 | $36.80 Million | -11.52% |
| 2011-12-31 | $41.59 Million | -4.34% |
| 2010-12-31 | $43.47 Million | +53.04% |
| 2009-12-31 | $28.41 Million | -14.76% |
| 2008-12-31 | $33.33 Million | +7.83% |
| 2007-12-31 | $30.91 Million | -13.38% |
| 2006-12-31 | $35.68 Million | +3.74% |
| 2005-12-31 | $34.40 Million | +172.18% |
| 2004-12-31 | $12.64 Million | -4.12% |
| 2003-12-31 | $13.18 Million | -1.08% |
| 2002-12-31 | $13.32 Million | +186.11% |
| 2001-12-31 | $4.66 Million | +58.73% |
| 2000-12-31 | $2.93 Million | -74.97% |
| 1999-12-31 | $11.72 Million | +1185.31% |
| 1998-12-31 | $912.00K | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more